Comparison of 0.2% and 0.18% hyaluronate eye drops in patients with moderate to severe dry eye with keratitis or keratoconjunctivitis
This Prospective, multicenter, randomized, single-masked, phase IIIb, noninferiority study was published in 2017 in Journal of Clinical Ophthalmology (IF2017: 0.84) by French and German ophthalmologists. The aim of this study was to Compare efficacy and safety of 0.2% and 0.18% hyaluronic acid (HA) eye drops three times a day (tid) in patients with moderate to severe dry eye disease, related to keratitis or keratoconjunctivitis. Thirty-eight patients were included in the 0.18% HA group, and 32 in the 0.2% HA group.
0.2% and 0.18% HA eye drops significantly improved signs and symptoms of dry eye disease and were well tolerated with few AEs. Noninferiority of 0.2% HA compared to 0.18% HA was demonstrated for reduction of OS lesions. In some parameters, there was a nonsignificant trend in favor of 0.2% HA concentration.